Can Nafamostat Mesilate Be Used for Temporary Management of Hemodialysis in a Patient with Heparin-induced Thrombocytopenia (HIT)?

• References

• 1 Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N, Hirasawa Y. Nafamostat mesilate; a regional anticoagulant for hemodialysis in platelets at high risk for bleeding. Nephron 1993; 64: 376-81.
• 2 Mellgren K, Skogby M, Friberg LG, Tengboru L, Wadenvix H. The influence of a serine protease inhibitor, nafamostat mesilate, on plasma coagulation, and platelet activation during experimental extracorporeal life support (ECLA). Thromb Haemost 1998; 79: 342-7.
• 3 Sundaram S, Gikakis N, Hack CE, Niewiarowski S, Edmunds Jr LH, Koneti Rao A, Sun L, Cooper SL, Colman RW. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelets, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost 1996; 75: 76-82.
• 4 Chong BH, Bingess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69: 344-50.
• 5 Janson PA, Moake JL, Carpinito G. Aspirin prevents heparin-induced platelet aggregation in vivo. Br J Haematol 1983; 53: 166-8.
• 6 Matsuo T, Yamada T, Chikahira Y, Kadowaki S. Effect of aspirin on heparin-induced thrombocytopenia (HIT) in a patient requiring hemodialysis. Blut 1989; 59: 393-5.
• 7 Matsuo T, Kobayashi H, Kario K, Suzuki S. Fibrin D-dimer in thrombogenic disorders. Semin Thromb Hemost 2000; 26: 101-7.
• 8 Hodohara K, Fujiyama Y, Bamba T, Yasunaga K. Amidinonaphthol derivatives directly inhibit the ligand binding on platelet glycoprotein IIb-[H9009][H9009][H9009]a. Pathophysiology 1995; 2: 145-51.
• 9 Patel VB, Snyder J, Shoprick RI. Successful use of low dose r-hirudin (Refludan) for recurrent dialysis catheter thrombosis in a patient with heparin induced thrombocytopenia. Thromb Haemost 1999; 82: 1205-6.
• 10 Warkentin TE, Kelton JG. Transience of heparin-induced thrombocytopenia antibodies [abst]. Blood 2000; 96 (Suppl. 01) 5310.